<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00475033</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-3008</org_study_id>
    <nct_id>NCT00475033</nct_id>
  </id_info>
  <brief_title>Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants</brief_title>
  <official_title>A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study will be to evaluate the safety, tolerability and immunogenicity of
      13-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric
      vaccinations in Canada. Immune responses induced by the infant series (NeisVac-C® and
      Pentacel®)and toddler dose(NeisVac-C®)of routine pediatric vaccines when administered with
      13-valent pneumococcal conjugate vaccine will be studied for noninferiority to the immune
      responses when administered with 7-valent pneumococcal conjugate vaccine. Safety profile and
      immunogenicity of 13-valent pneumococcal conjugate vaccine will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Achieving Predefined Antibody Level ≥1:8 for Meningococcal C Serum Bactericidal Assay (SBA) in the 13vPnC Group Relative to 7vPnC Group After 2 Doses of NeisVac-C® in the Infant Series</measure>
    <time_frame>1 month after 2 doses of NeisVac-C® in the infant series (7 months of age)</time_frame>
    <description>Percentage of subjects achieving predefined antibody threshold ≥1:8 along with the corresponding 95 percent (%) confidence interval (CI) for concomitant antigen meningococcal C SBA are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Meningococcal C Antigen in the 13vPnC Group Relative to 7vPnC Group After 2 Doses of NeisVac-C® in the Infant Series</measure>
    <time_frame>1 month after 2 doses of NeisVac-C® in the infant series (7 months of age)</time_frame>
    <description>Antibody geometric mean titer of meningococcal C antigen are presented. GMT and corresponding 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution. In addition, the 2-sided 95% confidence interval on the ratio of the geometric means for 13vPnC relative to 7vPnC was constructed by back transformation of the Student t distribution for the mean difference of the measures on the logarithmic scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Achieving Predefined Antibody Level to Pertussis Antigens in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</measure>
    <time_frame>1 month after the 3-dose infant series (7 months of age)</time_frame>
    <description>Percentage of subjects achieving predefined antibody threshold ≥5 enzyme-linked immunosorbent assay (ELISA) units per mL (EU/mL) along with the corresponding 95 % CI for concomitant antigens pertussis (pertussis toxoid [PT], filamentous hemagglutinin [FHA], and pertactin [PRN]) and ≥ 2.2 EU/mL fimbrial agglutinogens (FIM) are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) of Pertussis Antigens in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</measure>
    <time_frame>1 month after the 3-dose Infant Series (7 months of age)</time_frame>
    <description>Antibody geometric mean concentration of pertussis antigens (PT, FHA, PRN, and FIM) as measured by EU/mL are presented. GMC and corresponding 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution. In addition, the 2-sided 95% confidence intervals on the ratio of the GMCs for 13vPnC relative to 7vPnC were constructed by back transformation of the Student t distribution for the mean difference of the measures on the logarithmic scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Achieving Predefined Antibody Level ≥0.15 Micrograms Per mL (μg/mL) for Polyribosylribitol Phosphate (PRP) in Hib in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</measure>
    <time_frame>1 month after the 3-dose infant series (7 months of age)</time_frame>
    <description>Percentage of subjects achieving predefined antibody threshold ≥0.15 μg/mL along with the corresponding 95 percent (%) confidence interval (CI) for concomitant antigen PRP in Hib are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) of PRP in Hib in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</measure>
    <time_frame>1 month after the 3-dose infant series (7 months of age)</time_frame>
    <description>Antibody geometric mean concentration of PRP in Hib as measured by µg/mL are presented. GMC and corresponding 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution. In addition, the 2-sided 95% confidence interval on the ratio of the GMCs for 13vPnC relative to 7vPnC was constructed by back transformation of the Student t distribution for the mean difference of the measures on the logarithmic scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving Predefined Antibody Level ≥1:8 for Meningococcal C SBA in the 13vPnC Group Relative to 7vPnC Group After the Toddler Dose of NeisVac-C®</measure>
    <time_frame>1 month after the toddler dose of NeisVac-C® (13 months of age)</time_frame>
    <description>Percentage of subjects achieving predefined antibody threshold ≥1:8 along with the corresponding 95% CI for concomitant antigen meningococcal C SBA are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Meningococcal C Antigen in the 13vPnC Group Relative to 7vPnC Group After the Toddler Dose</measure>
    <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
    <description>Antibody geometric mean titer of meningococcal C antigen are presented. GMT and corresponding 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution. In addition, the 2-sided 95% confidence interval on the ratio of the GMs for 13vPnC relative to 7vPnC was constructed by back transformation of the Student t distribution for the mean difference of the measures on the logarithmic scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving Predefined Antibody Level ≥1.0 μg/mL for PRP in Hib in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</measure>
    <time_frame>1 month after the 3-dose infant series (7 months of age)</time_frame>
    <description>Percentage of subjects achieving predefined antibody threshold ≥1.0 μg/mL along with the corresponding 95% CI for concomitant antigen PRP in Hib are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">603</enrollment>
  <condition>Vaccines, Pneumococcal Conjugate Vaccine</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>13-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7-valent pneumococcal conjugate vaccine</intervention_name>
    <description>7-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 2-month old infants (42 to 98 days)

          -  Available for the duration of the study and reachable by telephone

        Exclusion Criteria:

          -  Previous vaccination with licensed or investigational pneumococcal, Hib conjugate,
             diphtheria, tetanus, pertussis, polio, or meningococcal vaccine

          -  Previous anaphylactic reaction to any vaccine or vaccine-related component.

          -  Bleeding disorder, immune deficiency or suppression, or significant chronic or
             congenital disease

          -  Receipt of blood products or gamma globulin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>98 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Canada, clintrialparticipation@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5N 4A3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3C 4J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 8P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2007</study_first_submitted>
  <study_first_submitted_qc>May 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <results_first_submitted>May 4, 2010</results_first_submitted>
  <results_first_submitted_qc>May 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 4, 2010</results_first_posted>
  <last_update_submitted>April 18, 2011</last_update_submitted>
  <last_update_submitted_qc>April 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wyeth (Registry Contact: Clinical Trial Registry Specialist)</name_title>
    <organization>Wyeth</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited in Canada from June 2007 through November 2007.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC</title>
          <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
        </group>
        <group group_id="P2">
          <title>7vPnC</title>
          <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="297"/>
                <participants group_id="P2" count="296"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
                <participants group_id="P2" count="294"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
                <participants group_id="P2" count="290"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent or legal guardian request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After the Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
                <participants group_id="P2" count="290"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrawn After Infant Series</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="282"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent or legal guardian request</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287">Vaccinated Toddler Dose</participants>
                <participants group_id="P2" count="282">Vaccinated Toddler Dose</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="283"/>
                <participants group_id="P2" count="282"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Parent or legal guardian request</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC</title>
          <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
        </group>
        <group group_id="B2">
          <title>7vPnC</title>
          <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="300"/>
            <count group_id="B2" value="303"/>
            <count group_id="B3" value="603"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at enrollment</description>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="0.3"/>
                    <measurement group_id="B2" value="2.1" spread="0.3"/>
                    <measurement group_id="B3" value="2.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Achieving Predefined Antibody Level ≥1:8 for Meningococcal C Serum Bactericidal Assay (SBA) in the 13vPnC Group Relative to 7vPnC Group After 2 Doses of NeisVac-C® in the Infant Series</title>
        <description>Percentage of subjects achieving predefined antibody threshold ≥1:8 along with the corresponding 95 percent (%) confidence interval (CI) for concomitant antigen meningococcal C SBA are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
        <time_frame>1 month after 2 doses of NeisVac-C® in the infant series (7 months of age)</time_frame>
        <population>Evaluable immunogenicity population: had treatments as randomized at all expected doses, blood drawn within specified timeframes, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations. N=number of participants analyzed with a determinate post-infant series antibody concentration to the given antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Predefined Antibody Level ≥1:8 for Meningococcal C Serum Bactericidal Assay (SBA) in the 13vPnC Group Relative to 7vPnC Group After 2 Doses of NeisVac-C® in the Infant Series</title>
          <description>Percentage of subjects achieving predefined antibody threshold ≥1:8 along with the corresponding 95 percent (%) confidence interval (CI) for concomitant antigen meningococcal C SBA are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
          <population>Evaluable immunogenicity population: had treatments as randomized at all expected doses, blood drawn within specified timeframes, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations. N=number of participants analyzed with a determinate post-infant series antibody concentration to the given antigen.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="94.1" upper_limit="98.5"/>
                    <measurement group_id="O2" value="99.3" lower_limit="97.4" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Meningococcal C: Difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI for the difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of Meningococcal C Antigen in the 13vPnC Group Relative to 7vPnC Group After 2 Doses of NeisVac-C® in the Infant Series</title>
        <description>Antibody geometric mean titer of meningococcal C antigen are presented. GMT and corresponding 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution. In addition, the 2-sided 95% confidence interval on the ratio of the geometric means for 13vPnC relative to 7vPnC was constructed by back transformation of the Student t distribution for the mean difference of the measures on the logarithmic scale.</description>
        <time_frame>1 month after 2 doses of NeisVac-C® in the infant series (7 months of age)</time_frame>
        <population>The evaluable immunogenicity population was the primary analysis population; N=number of participants analyzed with a determinate antibody titer to the given antigen. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Meningococcal C Antigen in the 13vPnC Group Relative to 7vPnC Group After 2 Doses of NeisVac-C® in the Infant Series</title>
          <description>Antibody geometric mean titer of meningococcal C antigen are presented. GMT and corresponding 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution. In addition, the 2-sided 95% confidence interval on the ratio of the geometric means for 13vPnC relative to 7vPnC was constructed by back transformation of the Student t distribution for the mean difference of the measures on the logarithmic scale.</description>
          <population>The evaluable immunogenicity population was the primary analysis population; N=number of participants analyzed with a determinate antibody titer to the given antigen. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</population>
          <units>GMT</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.16" lower_limit="305.46" upper_limit="427.00"/>
                    <measurement group_id="O2" value="302.55" lower_limit="263.89" upper_limit="346.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ratio of GMs (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Achieving Predefined Antibody Level to Pertussis Antigens in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</title>
        <description>Percentage of subjects achieving predefined antibody threshold ≥5 enzyme-linked immunosorbent assay (ELISA) units per mL (EU/mL) along with the corresponding 95 % CI for concomitant antigens pertussis (pertussis toxoid [PT], filamentous hemagglutinin [FHA], and pertactin [PRN]) and ≥ 2.2 EU/mL fimbrial agglutinogens (FIM) are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
        <time_frame>1 month after the 3-dose infant series (7 months of age)</time_frame>
        <population>The evaluable immunogenicity population was the primary analysis population; (n)=number of participants with an antibody concentration (titer) ≥ to prespecified level for the given antigen for 13vPnC and 7vPnC, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Predefined Antibody Level to Pertussis Antigens in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</title>
          <description>Percentage of subjects achieving predefined antibody threshold ≥5 enzyme-linked immunosorbent assay (ELISA) units per mL (EU/mL) along with the corresponding 95 % CI for concomitant antigens pertussis (pertussis toxoid [PT], filamentous hemagglutinin [FHA], and pertactin [PRN]) and ≥ 2.2 EU/mL fimbrial agglutinogens (FIM) are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
          <population>The evaluable immunogenicity population was the primary analysis population; (n)=number of participants with an antibody concentration (titer) ≥ to prespecified level for the given antigen for 13vPnC and 7vPnC, respectively.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PT ≥5 EU/mL (n=282, 277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="98.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.6" lower_limit="98.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA ≥5 EU/mL (n=283, 278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRN ≥5 EU/mL (n=283, 277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="95.4" upper_limit="99.2"/>
                    <measurement group_id="O2" value="96.8" lower_limit="93.9" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FIM ≥2.2 EU/mL (n=282, 275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" lower_limit="92.2" upper_limit="97.5"/>
                    <measurement group_id="O2" value="97.5" lower_limit="94.8" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PT: Difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI for the difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FHA: Difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI for the difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PRN: Difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI for the difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FIM: Difference in proportions (13vPnC, 7vPnC) expressed as a percentage</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI for the difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving Predefined Antibody Level ≥1:8 for Meningococcal C SBA in the 13vPnC Group Relative to 7vPnC Group After the Toddler Dose of NeisVac-C®</title>
        <description>Percentage of subjects achieving predefined antibody threshold ≥1:8 along with the corresponding 95% CI for concomitant antigen meningococcal C SBA are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
        <time_frame>1 month after the toddler dose of NeisVac-C® (13 months of age)</time_frame>
        <population>The evaluable immunogenicity population was the primary analysis population. N=number of participants analyzed with a determinate post-toddler dose antibody concentration (titer) to the given antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Predefined Antibody Level ≥1:8 for Meningococcal C SBA in the 13vPnC Group Relative to 7vPnC Group After the Toddler Dose of NeisVac-C®</title>
          <description>Percentage of subjects achieving predefined antibody threshold ≥1:8 along with the corresponding 95% CI for concomitant antigen meningococcal C SBA are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
          <population>The evaluable immunogenicity population was the primary analysis population. N=number of participants analyzed with a determinate post-toddler dose antibody concentration (titer) to the given antigen.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Meningococcal C: Difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI for the difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of Meningococcal C Antigen in the 13vPnC Group Relative to 7vPnC Group After the Toddler Dose</title>
        <description>Antibody geometric mean titer of meningococcal C antigen are presented. GMT and corresponding 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution. In addition, the 2-sided 95% confidence interval on the ratio of the GMs for 13vPnC relative to 7vPnC was constructed by back transformation of the Student t distribution for the mean difference of the measures on the logarithmic scale.</description>
        <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
        <population>The evaluable immunogenicity population was the primary analysis population; N=number of participants analyzed with a determinate antibody titer to the given antigen. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Meningococcal C Antigen in the 13vPnC Group Relative to 7vPnC Group After the Toddler Dose</title>
          <description>Antibody geometric mean titer of meningococcal C antigen are presented. GMT and corresponding 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution. In addition, the 2-sided 95% confidence interval on the ratio of the GMs for 13vPnC relative to 7vPnC was constructed by back transformation of the Student t distribution for the mean difference of the measures on the logarithmic scale.</description>
          <population>The evaluable immunogenicity population was the primary analysis population; N=number of participants analyzed with a determinate antibody titer to the given antigen. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</population>
          <units>GMT</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1379.75" lower_limit="1235.06" upper_limit="1541.39"/>
                    <measurement group_id="O2" value="1083.96" lower_limit="962.54" upper_limit="1220.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Meningococcal C: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects Achieving Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 μg/mL in the 13vPnC Group After the 3-dose Infant Series</title>
        <description>Percentage of subjects achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>1 month after the 3-dose infant series (7 months of age)</time_frame>
        <population>The evaluable immunogenicity population was the primary analysis population; (n)=number of participants with a determinate IgG antibody concentration to the given serotype for 13vPnC.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 μg/mL in the 13vPnC Group After the 3-dose Infant Series</title>
          <description>Percentage of subjects achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>The evaluable immunogenicity population was the primary analysis population; (n)=number of participants with a determinate IgG antibody concentration to the given serotype for 13vPnC.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4 (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="94.4" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B (n=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" lower_limit="89.5" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="92.1" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14 (n=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="95.8" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 18C n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="93.5" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 19F (n=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="96.3" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 23F (n=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.2" lower_limit="86.0" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 1 (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="92.6" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 3 (n=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" lower_limit="74.4" upper_limit="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 5 (n=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" lower_limit="82.4" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 6A (n=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="93.4" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 7F (n=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="96.3" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 19A (n=272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="95.3" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMC) for Pneumococcal IgG Antibody in 13vPnC Group After the 3-dose Infant Series</title>
        <description>Antibody geometric mean concentration (GMC) as measured by μg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>1 month after the 3-dose infant series (7 months of age)</time_frame>
        <population>The evaluable immunogenicity population was the primary analysis population; (n)=number of participants with a determinate antibody concentration for the given serotype for 13vPnC.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Pneumococcal IgG Antibody in 13vPnC Group After the 3-dose Infant Series</title>
          <description>Antibody geometric mean concentration (GMC) as measured by μg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>The evaluable immunogenicity population was the primary analysis population; (n)=number of participants with a determinate antibody concentration for the given serotype for 13vPnC.</population>
          <units>GMC μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4 (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" lower_limit="1.33" upper_limit="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B (n=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" lower_limit="1.87" upper_limit="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="1.03" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14 (n=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.43" lower_limit="4.86" upper_limit="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 18C (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="1.23" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 19F (n=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" lower_limit="1.99" upper_limit="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 23F (n=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="1.03" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 1 (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" lower_limit="1.63" upper_limit="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 3 (n=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.58" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 5 (n=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.81" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 6A (n=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" lower_limit="1.73" upper_limit="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 7F (n=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" lower_limit="2.09" upper_limit="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 19A (n=272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.82" upper_limit="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects Achieving Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 μg/mL in the 13vPnC Group After the Toddler Dose</title>
        <description>Percentage of subjects achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
        <population>The evaluable immunogenicity population was the primary analysis population; (n)=number of participants with a determinate IgG antibody concentration to the given serotype for 13vPnC.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 μg/mL in the 13vPnC Group After the Toddler Dose</title>
          <description>Percentage of subjects achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>The evaluable immunogenicity population was the primary analysis population; (n)=number of participants with a determinate IgG antibody concentration to the given serotype for 13vPnC.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4 (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B (n=263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="97.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14 (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 18C (n=262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.7" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 19F (n=263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="95.6" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 23F (n=263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 1 (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 3 (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" lower_limit="79.9" upper_limit="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 5 (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="96.2" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 6A (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 7F (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 19A (n=263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMC) for Pneumococcal IgG Antibody in 13vPnC Group After the Toddler Dose</title>
        <description>Antibody geometric mean concentration (GMC) as measured by μg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
        <population>The evaluable immunogenicity population was the primary analysis population; (n)=number of participants with a determinate antibody concentration for the given serotype for 13vPnC.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Pneumococcal IgG Antibody in 13vPnC Group After the Toddler Dose</title>
          <description>Antibody geometric mean concentration (GMC) as measured by μg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>The evaluable immunogenicity population was the primary analysis population; (n)=number of participants with a determinate antibody concentration for the given serotype for 13vPnC.</population>
          <units>GMC μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4 (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" lower_limit="2.43" upper_limit="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B (n=263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.83" lower_limit="8.83" upper_limit="10.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" lower_limit="1.87" upper_limit="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14 (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.58" lower_limit="6.86" upper_limit="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 18C (n=262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.80" upper_limit="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 19F (n=263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.70" lower_limit="5.06" upper_limit="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 23F (n=263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" lower_limit="3.21" upper_limit="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 1 (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" lower_limit="3.11" upper_limit="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 3 (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.67" upper_limit="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 5 (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" lower_limit="2.15" upper_limit="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 6A (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.47" lower_limit="5.87" upper_limit="7.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 7F (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" lower_limit="3.59" upper_limit="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 19A (n=263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.36" lower_limit="7.61" upper_limit="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) of Pertussis Antigens in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</title>
        <description>Antibody geometric mean concentration of pertussis antigens (PT, FHA, PRN, and FIM) as measured by EU/mL are presented. GMC and corresponding 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution. In addition, the 2-sided 95% confidence intervals on the ratio of the GMCs for 13vPnC relative to 7vPnC were constructed by back transformation of the Student t distribution for the mean difference of the measures on the logarithmic scale.</description>
        <time_frame>1 month after the 3-dose Infant Series (7 months of age)</time_frame>
        <population>The evaluable immunogenicity population was the primary analysis population; (n)=number of participants with a determinate antibody concentration (titer) to the given antigen. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) of Pertussis Antigens in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</title>
          <description>Antibody geometric mean concentration of pertussis antigens (PT, FHA, PRN, and FIM) as measured by EU/mL are presented. GMC and corresponding 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution. In addition, the 2-sided 95% confidence intervals on the ratio of the GMCs for 13vPnC relative to 7vPnC were constructed by back transformation of the Student t distribution for the mean difference of the measures on the logarithmic scale.</description>
          <population>The evaluable immunogenicity population was the primary analysis population; (n)=number of participants with a determinate antibody concentration (titer) to the given antigen. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</population>
          <units>GMC EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PT (n=282, 277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.06" lower_limit="42.83" upper_limit="49.53"/>
                    <measurement group_id="O2" value="40.37" lower_limit="37.24" upper_limit="43.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA (n=283,278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.08" lower_limit="72.47" upper_limit="84.13"/>
                    <measurement group_id="O2" value="69.52" lower_limit="64.39" upper_limit="75.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRN (n=283, 277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.90" lower_limit="38.17" upper_limit="48.22"/>
                    <measurement group_id="O2" value="40.69" lower_limit="36.16" upper_limit="45.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FIM (n=282, 275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.54" lower_limit="10.48" upper_limit="12.71"/>
                    <measurement group_id="O2" value="12.98" lower_limit="11.81" upper_limit="14.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PT: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FHA: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PRN: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FIM: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Achieving Predefined Antibody Level ≥0.15 Micrograms Per mL (μg/mL) for Polyribosylribitol Phosphate (PRP) in Hib in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</title>
        <description>Percentage of subjects achieving predefined antibody threshold ≥0.15 μg/mL along with the corresponding 95 percent (%) confidence interval (CI) for concomitant antigen PRP in Hib are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
        <time_frame>1 month after the 3-dose infant series (7 months of age)</time_frame>
        <population>The evaluable immunogenicity population was the primary analysis population. N=number of participants analyzed with a determinate post-infant series antibody concentration to the given antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Predefined Antibody Level ≥0.15 Micrograms Per mL (μg/mL) for Polyribosylribitol Phosphate (PRP) in Hib in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</title>
          <description>Percentage of subjects achieving predefined antibody threshold ≥0.15 μg/mL along with the corresponding 95 percent (%) confidence interval (CI) for concomitant antigen PRP in Hib are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
          <population>The evaluable immunogenicity population was the primary analysis population. N=number of participants analyzed with a determinate post-infant series antibody concentration to the given antigen.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="95.3" upper_limit="99.2"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI for the difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) of PRP in Hib in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</title>
        <description>Antibody geometric mean concentration of PRP in Hib as measured by µg/mL are presented. GMC and corresponding 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution. In addition, the 2-sided 95% confidence interval on the ratio of the GMCs for 13vPnC relative to 7vPnC was constructed by back transformation of the Student t distribution for the mean difference of the measures on the logarithmic scale.</description>
        <time_frame>1 month after the 3-dose infant series (7 months of age)</time_frame>
        <population>The evaluable immunogenicity population was the primary analysis population; N=number of participants analyzed with a determinate antibody concentration (titer) to the given antigen. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) of PRP in Hib in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</title>
          <description>Antibody geometric mean concentration of PRP in Hib as measured by µg/mL are presented. GMC and corresponding 2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution. In addition, the 2-sided 95% confidence interval on the ratio of the GMCs for 13vPnC relative to 7vPnC was constructed by back transformation of the Student t distribution for the mean difference of the measures on the logarithmic scale.</description>
          <population>The evaluable immunogenicity population was the primary analysis population; N=number of participants analyzed with a determinate antibody concentration (titer) to the given antigen. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</population>
          <units>GMC µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" lower_limit="2.48" upper_limit="3.32"/>
                    <measurement group_id="O2" value="3.14" lower_limit="2.74" upper_limit="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PRP in Hib: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving Predefined Antibody Level ≥1.0 μg/mL for PRP in Hib in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</title>
        <description>Percentage of subjects achieving predefined antibody threshold ≥1.0 μg/mL along with the corresponding 95% CI for concomitant antigen PRP in Hib are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
        <time_frame>1 month after the 3-dose infant series (7 months of age)</time_frame>
        <population>The evaluable immunogenicity population was the primary analysis population. N=number of participants analyzed with a determinate post-infant series antibody concentration (titer) to the given antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Predefined Antibody Level ≥1.0 μg/mL for PRP in Hib in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series</title>
          <description>Percentage of subjects achieving predefined antibody threshold ≥1.0 μg/mL along with the corresponding 95% CI for concomitant antigen PRP in Hib are presented. Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups &gt; -10%.</description>
          <population>The evaluable immunogenicity population was the primary analysis population. N=number of participants analyzed with a determinate post-infant series antibody concentration (titer) to the given antigen.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" lower_limit="76.5" upper_limit="86.0"/>
                    <measurement group_id="O2" value="84.6" lower_limit="79.7" upper_limit="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PRP: Difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided 95% CI for the difference between the 2 treatment groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI for the difference in proportions (13vPnC, 7vPnC) expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects Reporting Pre-specified Local Reactions in the 13vPnC and 7vPnC Groups: Infant Series Dose 1 (2 Months of Age)</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Subjects may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose (2 months of age)</time_frame>
        <population>Safety population: all subjects who received at least 1 dose of study vaccine. N=number of subjects reporting any local reactions; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting Pre-specified Local Reactions in the 13vPnC and 7vPnC Groups: Infant Series Dose 1 (2 Months of Age)</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Subjects may be represented in more than 1 category.</description>
          <population>Safety population: all subjects who received at least 1 dose of study vaccine. N=number of subjects reporting any local reactions; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=281, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5"/>
                    <measurement group_id="O2" value="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=270, 274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Any (n=271, 276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Mild (n=270, 275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Moderate (n=267, 274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Severe (n=266, 273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Any (n=270, 275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Mild (n=270, 275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7"/>
                    <measurement group_id="O2" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Moderate (n=266, 273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Severe (n=266, 273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects Reporting Pre-specified Local Reactions in the 13vPnC and 7vPnC Groups: Infant Series Dose 2 (4 Months of Age)</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Subjects may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose (4 months of age)</time_frame>
        <population>Safety population; N=number of subjects reporting any local reactions; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting Pre-specified Local Reactions in the 13vPnC and 7vPnC Groups: Infant Series Dose 2 (4 Months of Age)</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Subjects may be represented in more than 1 category.</description>
          <population>Safety population; N=number of subjects reporting any local reactions; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=264, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=248, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Any (n=251, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8"/>
                    <measurement group_id="O2" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Mild (n=251, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Moderate (n=245, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Severe (n=245, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Any (n=258, 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Mild (n=256, 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8"/>
                    <measurement group_id="O2" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Moderate (n=247, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Severe (n=245, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects Reporting Pre-specified Local Reactions in the 13vPnC and 7vPnC Groups: Infant Series Dose 3 (6 Months of Age)</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Subjects may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose (6 months of age)</time_frame>
        <population>Safety population; N=number of subjects reporting any local reactions; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting Pre-specified Local Reactions in the 13vPnC and 7vPnC Groups: Infant Series Dose 3 (6 Months of Age)</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Subjects may be represented in more than 1 category.</description>
          <population>Safety population; N=number of subjects reporting any local reactions; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=245, 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=238, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Any (n=243, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Mild (n=243, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Moderate (n=238, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Severe (n=237, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Any (n=244, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Mild (n=244, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Moderate (n=237, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Severe (n=237, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects Reporting Pre-specified Local Reactions in the 13vPnC and 7vPnC Groups: Toddler Dose (12 Months of Age)</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Subjects may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose (12 months of age)</time_frame>
        <population>Safety population; N=number of subjects reporting any local reactions; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting Pre-specified Local Reactions in the 13vPnC and 7vPnC Groups: Toddler Dose (12 Months of Age)</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Subjects may be represented in more than 1 category.</description>
          <population>Safety population; N=number of subjects reporting any local reactions; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=216, 223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=198, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Any (n=198, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Mild (n=198, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Moderate (n=196, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Severe (n=195, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Any (n=204, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Mild (n=202, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Moderate (n=197, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Severe (n=195, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects Reporting Pre-specified Systemic Events in the 13vPnC and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)</title>
        <description>Systemic events (any fever ≥38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep were reported using an electronic diary. Subjects may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose (2 months of age)</time_frame>
        <population>Safety population; N=number of subjects reporting any systemic events; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting Pre-specified Systemic Events in the 13vPnC and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)</title>
          <description>Systemic events (any fever ≥38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep were reported using an electronic diary. Subjects may be represented in more than 1 category.</description>
          <population>Safety population; N=number of subjects reporting any systemic events; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 but ≤39 degrees C (n=269, 273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 but ≤40 degrees C (n=267, 273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=266, 273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=279, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7"/>
                    <measurement group_id="O2" value="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=291, 288)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8"/>
                    <measurement group_id="O2" value="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9"/>
                    <measurement group_id="O2" value="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=276, 276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                    <measurement group_id="O2" value="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects Reporting Pre-specified Systemic Events in the 13vPnC and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)</title>
        <description>Systemic events (any fever ≥38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep were reported using an electronic diary. Subjects may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose (4 months of age)</time_frame>
        <population>Safety population; N=number of subjects reporting any systemic events; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting Pre-specified Systemic Events in the 13vPnC and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)</title>
          <description>Systemic events (any fever ≥38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep were reported using an electronic diary. Subjects may be represented in more than 1 category.</description>
          <population>Safety population; N=number of subjects reporting any systemic events; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 but ≤39 degrees C (n=249, 255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 but ≤40 degrees C (n=245, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=245, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=254, 262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=283, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0"/>
                    <measurement group_id="O2" value="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=263, 275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4"/>
                    <measurement group_id="O2" value="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=256, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects Reporting Pre-specified Systemic Events in the 13vPnC and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)</title>
        <description>Systemic events (any fever ≥38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep were reported using an electronic diary. Subjects may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose (6 months of age)</time_frame>
        <population>Safety population; N=number of subjects reporting any systemic events; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting Pre-specified Systemic Events in the 13vPnC and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)</title>
          <description>Systemic events (any fever ≥38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep were reported using an electronic diary. Subjects may be represented in more than 1 category.</description>
          <population>Safety population; N=number of subjects reporting any systemic events; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 but ≤39 degrees C (n=237, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 but ≤40 degrees C (n=237, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=237, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=249, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=266, 270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0"/>
                    <measurement group_id="O2" value="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=255, 258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=251, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                    <measurement group_id="O2" value="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects Reporting Pre-specified Systemic Events in the 13vPnC and 7vPnC Group: Toddler Dose (12 Months of Age)</title>
        <description>Systemic events (any fever ≥38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep were reported using an electronic diary. Subjects may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose (12 months of age)</time_frame>
        <population>Safety population; N=number of subjects reporting any systemic events; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose), co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Hib conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting Pre-specified Systemic Events in the 13vPnC and 7vPnC Group: Toddler Dose (12 Months of Age)</title>
          <description>Systemic events (any fever ≥38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep were reported using an electronic diary. Subjects may be represented in more than 1 category.</description>
          <population>Safety population; N=number of subjects reporting any systemic events; (n)=number of subjects reporting yes for at least 1 day or no for all days for the 13vPnC and 7vPnC groups, respectively.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="252"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 but ≤39 degrees C (n=203, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 but ≤40 degrees C (n=196, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=) 195, 210</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=211, 225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0"/>
                    <measurement group_id="O2" value="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=240, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8"/>
                    <measurement group_id="O2" value="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=212, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                    <measurement group_id="O2" value="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=212, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0"/>
                    <measurement group_id="O2" value="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through 6 Month Follow-up after last study vaccination (18 Months). Local reactions and systemic events assessed within 4 days of dose: Infant Series Dose 1, 2, and 3 at 2, 4, and 6 months of age, respectively; Toddler Dose at 12 months of age.</time_frame>
      <desc>Safety population = all randomized subjects with at least 1 dose of study treatment. An Adverse Event (AE) term may be reported as both a serious and non-serious AE, but are distinct events. AE may = serious for 1 subject and = non-serious for another subject or subject may have experienced both a serious and non-serious episode of the same event.</desc>
      <group_list>
        <group group_id="E1">
          <title>13vPnC Infant Series</title>
          <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series), co-administered with Pentacel® at 2, 4, and 6 months of age; NeisVac-C® at 2 and 6 months of age (infant series).
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=229; systematic (solicited) Any Local Reactions N=144; systematic (solicited) Any Systemic Events N=273.</description>
        </group>
        <group group_id="E2">
          <title>7vPnC Infant Series</title>
          <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series), co-administered with Pentacel at 2, 4, and 6 months of age; NeisVac-C® at 2 and 6 months of age (infant series).
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=230; systematic (solicited) Any Local Reactions N=148; systematic (solicited) Any Systemic Events N=279.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC After the Infant Series</title>
          <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series), co-administered with Pentacel® at 2, 4, and 6 months of age; NeisVac-C® at 2 and 6 months of age (infant series).</description>
        </group>
        <group group_id="E4">
          <title>7vPnC After the Infant Series</title>
          <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series), co-administered with Pentacel at 2, 4, and 6 months of age; NeisVac-C® at 2 and 6 months of age (infant series).</description>
        </group>
        <group group_id="E5">
          <title>13vPnC Toddler Dose</title>
          <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 12 months of age (toddler dose), co-administered NeisVac-C® at 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=110; systematic (solicited) Any Local Reactions N=84; systematic (solicited) Any Systemic Events N=199.</description>
        </group>
        <group group_id="E6">
          <title>7vPnC Toddler Dose</title>
          <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 12 months of age (toddler dose), co-administered with NeisVac-C® at 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=108; systematic (solicited) Any Local Reactions N=86; systematic (solicited) Any Systemic Events N=193.</description>
        </group>
        <group group_id="E7">
          <title>13vPnC Toddler Dose 6-Month Follow-up</title>
          <description>Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 12 months of age (toddler dose), co-administered NeisVac-C® at 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
        </group>
        <group group_id="E8">
          <title>7vPnC Toddler Dose 6-Month Follow-up</title>
          <description>Subjects received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 12 months of age (toddler dose), co-administered with NeisVac-C® at 12 months of age (toddler dose); a single type of commercially available MMR at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Developmental delay</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Meningitis meningococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Physical testicle examination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="273" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="279" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="199" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="193" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dacryostenosis congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Plagiocephaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Ankyloglossia congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Eye oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Hypermetropia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dental discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Faecal volume increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gingival cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Infantile spitting up</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Vomiting neonatal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Vomiting projectile</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38 degrees Celsius (C) but ≤39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever ≥38 degrees C but ≤39 degrees C</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="273"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="213"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38 degrees Celsius C but ≤39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever ≥38 degrees C but ≤39 degrees C</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38 degrees C but ≤39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever ≥38 degrees C but ≤39 degrees C</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39 degrees C but ≤40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;39 degrees C but ≤40 degrees C</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39 degrees C but ≤40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;39 degrees C but ≤40 degrees C</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39 degrees C but ≤40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt;39 degrees C but ≤40 degrees C</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt;40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="78" subjects_at_risk="211"/>
                <counts group_id="E6" subjects_affected="77" subjects_at_risk="225"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="262"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Irritability</description>
                <counts group_id="E1" subjects_affected="235" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="239" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="165" subjects_at_risk="240"/>
                <counts group_id="E6" subjects_affected="141" subjects_at_risk="241"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Irritability</description>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="283"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="281"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Irritability</description>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Increased sleep</description>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="292"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="71" subjects_at_risk="212"/>
                <counts group_id="E6" subjects_affected="75" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Increased sleep</description>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Increased sleep</description>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="258"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="276"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="212"/>
                <counts group_id="E6" subjects_affected="77" subjects_at_risk="227"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="261"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="251"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to metals</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Candida nappy rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Roseola</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Coxsackie viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Injection site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Measles post vaccine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental needle stick</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Physical examination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Positional plagiocephaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Head titubation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Perineal laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Listless</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Tearfulness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital labial adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Vulval disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pharyngeal ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dandruff</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Skin discoloration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Skin nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Skin plaque</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Skin warm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Xeroderma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Livedo reticularis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="54" subjects_at_risk="216"/>
                <counts group_id="E6" subjects_affected="64" subjects_at_risk="223"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (any)</description>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="264"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (any)</description>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (significant)=present and interfered with limb movement.</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (significant)</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (significant)</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="213"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (any)</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="251"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (any)</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (mild)=0.5 centimeters (cm) to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="213"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (mild)</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="251"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (mild)</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="204"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="216"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (any)</description>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (any)</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (mild)=0.5 cm to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="216"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (mild)</description>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (mild)</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="197"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (moderate)</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (moderate)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

